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Abstract
Background: Given the considerable geographic overlap in the endemic regions for malaria and tuberculosis, it is probable
that co-infections with Mycobacterium tuberculosis and Plasmodium species are prevalent. Thus, it is quite likely that both
malaria and TB vaccines may be used in the same populations in endemic areas. While novel vaccines are currently being
developed and tested individually against each of these pathogens, the efficacy of these vaccines has not been evaluated in
co-infection models. To further assess the effectiveness of these new immunization strategies, we investigated whether co-
infection with malaria would impact the anti-tuberculosis protection induced by four different types of TB vaccines in a
mouse model of pulmonary tuberculosis.
Principal Findings: Here we show that the anti-tuberculosis protective immunity induced by four different tuberculosis
vaccines was not impacted by a concurrent infection with Plasmodium yoelii NL, a nonlethal form of murine malaria. After an
aerogenic challenge with virulent M. tuberculosis, the lung bacterial burdens of vaccinated animals were not statistically
different in malaria infected and malaria naı ¨ve mice. Multi-parameter flow cytometric analysis showed that the frequency
and the median fluorescence intensities (MFI) for specific multifunctional T (MFT) cells expressing IFN-c, TNF-a, and/or IL-2
were suppressed by the presence of malaria parasites at 2 weeks following the malaria infection but was not affected after
parasite clearance at 7 and 10 weeks post-challenge with P. yoelii NL.
Conclusions: Our data indicate that the effectiveness of novel TB vaccines in protecting against tuberculosis was unaffected
by a primary malaria co-infection in a mouse model of pulmonary tuberculosis. While the activities of specific MFT cell
subsets were reduced at elevated levels of malaria parasitemia, the T cell suppression was short-lived. Our findings have
important relevance in developing strategies for the deployment of new TB vaccines in malaria endemic areas.
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Introduction
Plasmodium falciparum and Mycobacterium tuberculosis are among the
world’s most important tropical diseases. Malaria and tuberculosis
are major global causes of morbidity and mortality with each
causing 1–2 million deaths annually. The World Health
Organization has reported that there are 300–500 million new
cases of malaria and 9 million new cases of tuberculosis each year
[1,2]. Moreover, it has been estimated that one-third of the world’s
population is infected with latent TB. Given the substantial
geographic overlap of endemic regions for these diseases and
especially the large number of individuals with latent TB living in
malaria-endemic regions, it is highly probable that co-infections
with M. tuberculosis and Plasmodium species are common [3,4]. This
presumed high rate of malaria-TB co-infections could be
problematic for the development of TB vaccines targeted for
malaria-endemic areas of the world. Malaria parasites are known
to be immunosuppressive and acute malaria infections have
already been associated with decreased immune responses to
meningococcal, Hib conjugate, and Salmonella typhi vaccines [5–9].
Since many potential vaccinees including children in the WHO
Expanded Program for Immunization reside in areas with high
rates of malaria, it is important to understand the effect of malaria
infections on the immunogenicity and effectiveness of vaccines
designed to prevent tuberculosis.
To combat the lethal tuberculosis epidemic, numerous novel
vaccine preparations and immunization strategies are being
created to replace or augment the current TB vaccine, M. bovis
BCG. While BCG does induce protection against disseminated
tuberculous disease in children, it has been relatively ineffective in
preventing the most prevalent form of the disease, adult
pulmonary TB [10,11]. Furthermore, vaccination with live BCG
poses a considerable risk of serious infection when it is given to
infants perinatally infected with HIV [12–14]. Among the new TB
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are live, attenuated M. tuberculosis vaccines, TB fusion proteins
formulated in immunostimulating adjuvants, and viral vectored
vaccines. At least 10 of these new vaccine preparations are
currently being evaluated in clinical trials [15–17]. While the
efficacy of each of these new vaccine formulations have been
assessed in pre-clinical M. tuberculosis vaccination/challenge
models, the new TB vaccines have been only minimally evaluated
in co-infection models. Despite the considerable public health
importance of concomitant infections, the complex issues associ-
ated with developing immunity after immunization in the presence
of co-infecting organisms generally have not been adequately
addressed. To develop more efficacious therapeutic and vaccina-
tion strategies, it is imperative to dissect whether effective
protective immune responses can be generated against deadly
pathogens in individuals co-infected with multiple organisms. In
particular, it is uncertain whether a malaria infection will alter the
effectiveness of new candidate vaccines to protect against a
tuberculous challenge. Given the documented immunsuppressive
capacity of the malaria parasite, the potential inhibitory impact of
malaria infections against the protective immunity induced by new
TB vaccines is a significant concern.
Although concurrent helminth or HIV infections have been
shown to suppress BCG-induced anti-tuberculosis protective
responses, the effect of malaria co-infections on the protective
efficacy of vaccines designed to protect against tuberculosis has not
been thoroughly investigated [18–20]. In this study, we examined
the impact of malaria co-infections on the capacity of BCG and
new TB vaccines to protect against an aerogenic virulent M.
tuberculosis challenge of mice. The P. yoelii 17XNL parasite was
used as a source of malaria infection in mice. The effect of the
malaria infection on the immunity induced by TB vaccines was
assessed in vitro using flow cytometry and in vivo with a standard
mouse model of pulmonary tuberculosis. Although the flow
cytometric data suggest that specific vaccine-induced immune
responses can be suppressed by acute malaria infections, no overall
reduction in pulmonary protection against TB was detected in
vaccinated co-infected mice.
Materials and Methods
Animals
C57BL/6 female mice that were 6–8 weeks of age were
obtained from the Jackson Laboratories (Bar Harbour, Maine). All
mice used in this study were maintained under appropriate
conditions at the Center for Biologics Evaluation and Research,
Bethesda, MD. This study was done in accordance with the
guidelines for the care and use of laboratory animals specified by
the National Institutes of Health. This protocol was approved by
the Institutional Animal Care and Use Committee of the Center
for Biologics Evaluation and Research under Animal Study
Protocol 1993-09.
Vaccines
The BCG Pasteur vaccine preparation was derived from the
mycobacterial culture collection of the Trudeau Institute. The E6-
85B protein is an ESAT6-antigen 85B M. tuberculosis fusion protein
which was purified by nickel affinity chromatography after cloning
and expressing the ESAT6-antigen 85B fusion gene in the
pET23b vector system (Novagen, SanDiego CA). The protein-
adjuvant formulation was prepared by mixing the fusion protein
(50 mg/ml) with dimethyldioctadecylammonium bromide (DDA;
150 mg/ml; Kodak) and monophosphoryl lipid (MPL; 250 mg/ml;
Avanti Polar Lipids, Alabaster, AL). The MVA-5TB vaccine was
generated by cloning five M. tuberculosis genes (antigen 85A,
antigen 85B, ESAT6, Mtb39 and HSP65) as well as the
interleukin-15 (IL-15) gene into a modified vaccinia virus Ankara
(MVA) vector [21].The double deletion mutant strain (DsecA2-
DlysA) of the H37Rv strain of M. tuberculosis was constructed using
specialized transduction to disrupt the chromosomal copy of the
lysA gene of an unmarked DsecA2 clone, as described previously
[22].
Immunizations
Five female C57BL/6 mice per group were used in the
immunization studies. For live BCG vaccine, 10
6 CFU was given
once subcutaneously. Five micrograms of the E6-85 protein in the
DDA (15 mg)–MPL (25 mg) adjuvant was administered three
times, 2 weeks apart. For the attenuated strain/protein mixture
vaccine, 10
6 CFU of the DsecA2DlysA live attenuated M.
tuberculosis strain was mixed with the E6-85/DDA adjuvant
formulation and administered three times, 2 weeks apart. For the
prime boost experiments, one month after the three priming
vaccinations with the E6-85 vaccine preparation, two doses of
5610
7 PFU of the MVA/IL15/5TB construct were given
subcutaneously 1 month apart.
Plasmodium yoelii NL infections. Frozen stocks of P. yoelii
17XNL-infected erythrocytes were thawed and used to intra-
peritoneally (ip) infect three donor C57BL/6 mice. Percent
parasitemias were then monitored every other day using blood
smears. When ,10 to 20% parasitemias were detected, blood was
collected by cardiac puncture, diluted in PBS and used to infect
experimental animals with 1610
6 P. yoelii 17XNL parasites in
200 ul of PBS by the ip. route. In these studies, five to fifteen
C57BL/6 mice per group were used.
Evaluation of vaccine-induced protection using a mouse
model of pulmonary tuberculosis
For the vaccination/challenge experiments, five mice were
evaluated for each group. At 2, 6, or 10 weeks following the P. yoelii
infections, vaccinated and control mice were aerogenically
challenged with the M. tuberculosis Erdman suspended in PBS at
a concentration known to deliver 100–200 CFU in the lungs over
a 30-min exposure time in a Middlebrook chamber (GlasCol,
Terre Haute, IN). To assess the level of pulmonary exposure
during the aerosol challenge, the number of CFU in the lung were
measured at 4 h after the M. tuberculosis infection. To determine
the extent of pulmonary bacterial growth, the mice were sacrificed
at 4 weeks post-challenge. The lungs were then removed
aseptically and homogenized separately in PBS using a Seward
Stomacher 80 blender (Tekmar, Cincinnati, OH). The lung
homogenates were diluted serially in 0.4% PBS–Tween 80, and
50-ml aliquots were placed on Middlebrook 7H11 agar (Difco)
plates supplemented with 10% OADC enrichment (BectonDick-
inson, Sparks, MD) medium, 2 mg/ml 2-thiophenecarboxylic acid
hydrazide (TCH) (Sigma), 10 mg/ml ampicillin, and 50 mg/ml
cycloheximide (Sigma). The addition of TCH to the agar plates
inhibits the growth of BCG but not M. tuberculosis. All plates were
incubated at 37uC for 14 to 17 days in sealed plastic bags, and the
colonies were counted to determine the organ bacterial burdens.
Assessment of lung inflammation
To evaluate the level of inflammation in the lungs of mice
infected with M. tuberculosis, lung sections stained with hematoxylin
and eosin (H & E) were photographed using a Nikon Optishot 2
microscope fitted with a camera which was connected to a
computer. Spot Advanced software was used to save the computer
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28164images. The Image Pro Plus program (Media Cybernetics, Silver
Spring, MD) was utilized to objectively assess the level of
inflammation present in each image. In these images, the inflamed
areas stained a more intense purple than the non-inflamed areas.
For the analyses, colors were assigned as follows: red to represent
the inflamed areas, green to represent non-inflamed areas, and
yellow to represent the background. After the color assignments
were established, the computer software identified inflamed and
non-inflamed sections on each slide. The percentage of the lung
sections staining red, green, or yellow was then determined by the
computer software. To quantitate the percent area inflamed, we
determined the mean percent red area from five lung sections of
each of the different groups.
Flow cytometry
Five BCG vaccinated and control mice (3 mice per group) were
used to determine the frequency of CD4 MFT cells at each time
point post-vaccination. Lung cells were isolated by homogenizing
the lung tissue in a stomacher bag using the end of a 20 cc syringe
in PBS containing 2% FBS (PBS-FBS). The tissue was then
incubated in PBS-FBS containing 4 mg/ml collagenase (final
concentration) at 37uC for one hour. Afterward, the lung tissue
was removed from the cells by placing the suspension in a Filtra-
Bag (Labplas, Quebec, Canada). The resulting single cell
suspension was centrifuged to pellet the cells and treated with
ACK lysing buffer as described above. After washing, the cells
were passed through a 70 mm cell strainer, pelleted and counted.
After washing the lung cells with an equal volume of media, the
cells were resuspended in cDMEM-FBS, counted and added to
wells of a 24-well plate at a density of 2.5610
6 cells per well in
1.0 ml cDMEM-FBS. For measurement of antigen-specific
responses, BCG Pasteur (or BCG+PPD) was added to the wells
at a multiplicity of infection (MOI) of 0.5 bacilli per spleen cell.
Wells which contained only lung cells served as unstimulated
controls. Infections were allowed to proceed overnight followed by
the addition of Golgiplug (BD Biosciences, San Jose CA) (1 ml per
well). After 4–5 hours of incubation, the unbound cells were
removed from the wells and transferred to 12675 mm tubes,
washed with PBS and resuspended in ,50 ml PBS. Live-Dead
stain (Invitrogen, Carlsbad, CA) (10 ml of a 1:100 dilution) was
added to each tube and incubated for 30 min. at room
temperature to allow for gating on viable cells. After washing
the cells with PBS-FBS, antibody against CD16/CD32 (FccIII/II
receptor, clone 2.4G2) (Fc block) was added in a volume of ,50 ml
and incubated at 4uC for 15 min. The cells were then stained for
30 min. at 4uC by adding antibodies against the CD4 (rat anti-
mouse CD4 Alexa Fluor 700 [AF-700] Ab, clone RM4–5), and
CD8 (rat anti-mouse CD8 peridinin chlorophyll protein complex
[PerCP] Ab, clone 53-6.7) proteins at 0.1 and 0.2 mg per tube
respectively. Following the incubation, the cells were washed twice
with PBS and then fixed for 30 min. at 4uC with 2%
paraformaldehyde in PBS. After fixing, the cells were pelleted,
washed twice with PBS-FBS and stored at 4uC. Fixed cells were
washed twice with perm-wash buffer (1% FBS, 0.01 M HEPES,
0.1% saponin in PBS) followed by intracellular staining using the
following antibodies at 0.2 mg per tube: rat anti-mouse IFN-c
allophycocyanin [APC] Ab, clone XMG1.2; rat anti-mouse TNF-
a fluorescein isothiocyanate [FITC] Ab, clone MP6-XT22; rat
anti-mouse IL-2 phycoerythrin [PE] Ab, clone JES6-5H4. The
cells were incubated at 4uC for 30 min., washed twice with perm-
wash buffer and then twice with PBS-FBS. All antibodies were
obtained from BD Biosciences.
The cells were analyzed using a LSRII flow cytometer (Becton
Dickinson) and FlowJo software (Tree Star Inc., Ashland, Oregon).
We acquired 250,000 events per sample and then, using FlowJo,
gated on live, single cell lymphocytes. To determine the frequency
of different populations of MFT cells, we gated on CD4 or CD8 T
cells staining positive for TNF-a and IFN-c, TNF-a and IL-2,
IFN-c and IL-2 or all three cytokines.
Median fluorescence intensity (MFI) assessments
The MFI for IFN-c or TNF-a from monofunctional and
multifunctional CD4 and CD8 T cells was evaluated using the
FlowJo software. For this study, the MFI is the average
fluorescence intensity value for individual T cells secreting only
IFN-c or TNF-a, secreting both IFN-c and TNF-a or cells
secreting IFN-c, TNF-a and IL-2. The data are presented as the
mean 6 the standard error of the individual MFI assessments for 5
groups of mice.
Statistical analyses
The protection, lung inflammation, and flow cytometry data
were evaluated using t test analysis of the GraphPad Prism, version
5, program.
Results
The impact of malaria co-infections on the effectiveness
of BCG vaccine in a mouse model of pulmonary
tuberculosis
To assess the impact of a malaria co-infection on the
effectiveness of vaccines designed to protect against M. tuberculosis,
a murine co-infection immunization model was developed.
Initially, mice were vaccinated subcutaneously with 10
6 CFU of
BCG Pasteur. Two months after the BCG immunization, the mice
were given 10
6 P. yoelii blood stage parasites by the intraperitoneal
route. At an appropriate time period following the malaria
infection (2–10 weeks), the mice were aerogenically challenged
with 100–200 CFU of virulent M. tuberculosis Erdman. Four weeks
later, the TB infected mice were sacrificed and pulmonary
mycobacterial burdens and lung pathologies were determined.
For these studies, since extensive splenomegaly was seen after
malaria infections and the lung is the primary site of M. tuberculosis
infections, we concentrated on evaluating the pulmonary impact of
the co-infection on the effectiveness of TB vaccines.
Since our aerosol TB challenge model had been previously
established, our initial efforts for these studies focused on
characterizing the kinetics of the P. yoelii infection. In the
representative data shown in Figure 1, malaria parasitemia in
naı ¨ve mice peaked at 20.5% on day 14 and the infection was
cleared by day 20. Consistent with previous studies, moderate
protection against malaria parasitemia was seen in BCG
vaccinated mice [23,24]. In this experiment, the level of
parasitemia was reduced by 41% relative to naives at day 12
and 70% at day 14 in BCG-vaccinated mice but parasite clearance
was again seen by day 20.
The initial vaccination/challenge studies evaluated the temporal
effect of P. yoelii infections on the effectiveness of BCG vaccine to
protect against an aerogenic M. tuberculosis challenge. Mice were
infected with P. yoelii two months after BCG immunization and
then were challenged with M. tuberculosis at either two, six or ten
weeks following the malaria infection. When mice were challenged
with M. tuberculosis at two weeks after the malaria infection (at peak
parasitemia levels), no significant impact was detected on the
capacity of naı ¨ve or BCG vaccinated mice to control the acute
tuberculosis lung infections at 4 weeks post-challenge (Figure 2). In
both malaria infected and non-infected BCG vaccinated mice,
significant anti-tuberculosis protection (.0.95 log10 compared to
Malaria’s Impact on TB Vaccines
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challenge. Similarly, at 6 and 10 weeks following the malaria
infection, the anti-tuberculosis protective responses induced by the
BCG vaccinated mice were not statistically different than the
protection evoked in P. yoelii infected BCG vaccinated animals.
Additionally, the pulmonary mycobacterial burdens were also not
different in the naı ¨ve and P. yoelii infected naı ¨ve groups at 2, 6 and
10 week post malaria infection time point (data not shown). For
example, the lung CFU levels that were detected when non-
vaccinated mice were challenged with M. tuberculosis at the peak of
malaria parasitemia (6.3660.12) were statistically equivalent to
lung burdens seen in naı ¨ve mice infected with M. tuberculosis
(6.2660.18). Overall, the presence of malaria parasites did not
exacerbate the tuberculous pulmonary infection when the M.
tuberculosis challenge occurred either near the peak of parasitemia
or after parasite clearance. Interestingly, nearly identical results
were obtained in co-infection studies of mice that had been
vaccinated with BCG eight months before the P. yoelii blood stage
infection and then were challenged with M. tuberculosis at the peak
of parasitemia. At 8 months after BCG immunization, statistically
equivalent lung CFU levels were detected in the BCG (5.5960.11
log10 CFU) and BCG/P. yoelii (5.5860.22) groups as well as the
naı ¨ve (6.4060.30) and naı ¨ve/P. yoelii (6.1160.15) animals.
To support these findings, lung pathology was analyzed using
H&E sections from mice that were challenged with M. tuberculosis
two weeks after a P. yoelii infection. Overall, the P. yoelii infections
did not impact lung pathology observed after an aerogenic M.
tuberculosis infection. At 4 weeks post challenge, substantially less
inflammation was observed in lung sections of BCG vaccinated
and the BCG/P. yoelii infected animals relative to naı ¨ve controls
(Figure S1). The granulomatous type structures were more
condensed, mature, and lymphocyte-rich in the lungs of both
BCG vaccinated groups compared to the larger, more immature
granulomas seen in the naı ¨ve and naı ¨ve/P. yoelii mice at this time
point. To quantitate the pathology results, the lung sections were
assessed by computerized scanning using the Image pro analysis
system as described earlier [25]. With this imaging system, the
proportion of lung sections that are inflamed can be quantitatively
defined. This pathology analysis showed no statistical differences
in the inflammatory response values seen in lung sections taken
from the BCG (20.266.4) and BCG/P. yoelii infected mice
(20.969.0). Similarly, the lung pathology values were not different
in naı ¨ve (38.6610.6) and naı ¨ve/P. yoelii infected (34.963.9)
animals.
The impact of malaria-M. tuberculosis co-infections on the
protective immunity induced by novel TB vaccines
To assess the impact of malaria infection on the effectiveness of
novel TB vaccine candidates, C57BL/6 mice were vaccinated with
three unique immunizing preparations using different vaccination
strategies. In an initial experiment with a novel vaccine, mice were
immunized with the E6-85 TB fusion protein (ESAT6-Antigen
85B) suspended in DDA/MPL adjuvant [26,27]. As controls,
other groups of mice were immunized with BCG. At two weeks
after a P. yoelii infection, mice were aerogenically challenged with a
low dose of M. tuberculosis. Four weeks later, pulmonary bacterial
burdens were evaluated. Again no significant differences in lung
CFU were seen between the malaria-infected and the non-infected
control groups. As seen in Figure 3, the P. yoelii infection clearly
did not increase pulmonary M. tuberculosis CFU levels in non-
vaccinated mice. Moreover, the levels of protection detected in the
vaccinated animals were consistent with previous results and were
unaffected by the P. yoelii infection (1.4 log10 for the BCG and
BCG/P. yoelii groups; 1.2 log10 for the E6-85 and E6-85/P. yoelii
mice) [26]. In a second study of novel TB vaccination strategies,
mice were immunized with either a attenuated M. tuberculosis
DsecADlysA vaccine strain mixed with the E6-85/DDA formulation
or a prime-boost procedure that involved priming with the E6-85
Figure 1. The levels of parasitemias following a P. yoelii
infection of naı ¨ve and BCG-vaccinated C57BL/6 mice. The
parasitemia levels were detected in blood smears from 5–10 BCG
vaccinated (closed squares) and naı ¨ve (open triangles) mice at a specific
day after the P. yoelii challenge. The parasitemia curves contain data
from a single experiment which is representative of results of the P.
yoelii infections done in this study.
doi:10.1371/journal.pone.0028164.g001
Figure 2. Infection with Plasmodium yoelii NLmalaria does not
reduce the anti-tuberculosis pulmonary protective immunity
induced by immunization with BCG vaccine. C57Bl/6 mice were
vaccinated subcutaneously with BCG and two months later infected
with P. yoelii by the intraperitoneal route. The mice were challenged by
the aerosol route with M. tuberculosis Erdman at 2, 6, or 10 weeks after
the infection with P. yoelii. Mycobacterial CFU in the lung were assessed
at 4 weeks post-challenge. The data are represented as the mean (6 the
standard error of the mean) protection seen in BCG-vaccinated non-
infected (black bars) and BCG-vaccinated P. yoelii infected mice (grey
bars). Protection is defined as the lung CFU (log10) difference between
naı ¨ve and BCG-vaccinated mice.
doi:10.1371/journal.pone.0028164.g002
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vaccine which over-expressed 5 M. tuberculosis antigens and IL-15
(MVA/IL-15/5Mtb) [28,29]. As shown in Figure 4, when the M.
tuberculosis challenge occurred during elevated levels of parasitemia
(2 weeks), the extent of anti-tuberculosis protection induced by the
attenuated M. tuberculosis vaccine/protein mixture and the prime-
boost immunization procedure were not impacted by the malaria
infection. About 1.3 log10 protection was seen in both malaria
infected and non-infected prime-boost groups and 1.6–1.7 log10
protective responses were measured for both the DsecADlysA M.
tuberculosis attenuated vaccine mixture and DsecADlysA vaccine/P.
yoelii infected animals Furthermore, the malaria infection again did
not exacerbate the tuberculous disease because no significant
differences in pulmonary mycobacterial burdens were again
detected between the malaria infected non-vaccinated and naı ¨ve
control groups at 4 weeks post challenge.
Flow cytometric analysis of vaccine-induced immune
responses in BCG vaccinated and malaria infected BCG
vaccinated mice
Recent studies have shown that malaria infections can have
immunomodulatory effects on host immune responses and in
particular, malaria can inhibit antigen specific T cell responses [5–
9]. To assess whether pulmonary mycobacterial-specific T cell
responses were influenced by the malaria infection in our model,
multi-parameter flow cytometric analysis was done on lung cells
recovered from experimental animals. For these studies, mice were
infected with P. yoelii two months after BCG vaccination and then
2, 7, or 10 weeks later the mice were sacrificed and the lung cells
were isolated and stimulated with BCG (a surrogate for the M.
tuberculosis challenge). Following intracellular cytokine staining, the
cells were analyzed by flow cytometry. Since the induction of
multifunctional T cells (MFT) by immunization has been shown to
correlate with protection against Leishmania and M. tuberculosis in
animal models, the cells were evaluated for the concurrent
expression of IFN-c TNF-a and/or IL-2 [30–32]. As seen in
Figure 5A and Figure S2, the levels of CD4 cells producing IFN-c,
IFN-c/TNF-a, or IFN-c/TNF-a/IL2 all exceeded 1% in BCG
vaccinated mice at week 2 of the P. yoelii infection (10 weeks post-
BCG immunization) but declined at weeks 7 and 10 post-infection
(15 and 18 weeks post-BCG vaccination). In contrast, the
frequency of IL-2 and TNF-a/IL2 producing cells in BCG
vaccinated animals significantly increased during the 10 week
observation period. In these studies, the frequencies of cells from
naı ¨ve controls expressing multiple cytokines were generally less
than 0.01% (data not shown). Although lower overall cell
frequencies were seen, a similar pattern was observed for CD8
T cells taken from BCG vaccinated animals that were not infected
with malaria (Figure 5B). The relative proportions of cells
producing IFN-,c IFN-c/TNF-a and IFN-c/TNF-a/IL2 were
elevated at 10 weeks after the BCG immunization while the
frequencies of these cells declined in the lung 5–7 weeks later.
Consistent with the CD4 data, the frequency of IL-2 and TNF-c/
IL2 producing CD8 T cells increased at the later time points of the
experiment, but the magnitude was higher than that seen for CD4
cells.
Surprisingly, the malaria infection did not generally impact the
frequencies of vaccine-induced CD4 and CD8 cytokine producing
cells at the later stages of this study. At 7 and 10 weeks after the
malaria challenge (15 and 17 weeks post-BCG vaccination),
malaria-related alterations in the cellular frequencies were not
observed in BCG vaccinated animals. However, a negative impact
was seen on the frequencies of cells synthesizing IFN-c/TNF-a/
IL2 in BCG vaccinated mice when malaria parasitemias were
substantially elevated (2 weeks post P. yoelii infection). For the CD4
T cells, the frequencies of triple positive cells were significantly
decreased (BCG=1.22%, BCG/P. yoelii=0.29%). Interestingly,
dramatic declines in the triple positive CD8 T cells were also seen
at the peak of P. yoelii infection (BCG=0.355%, BCG/
P.yoelii=0.002%).
An important characteristic of MFT cells is their capacity to
express substantially higher levels of cytokines than monofunc-
tional cells. To further evaluate the effect of malaria infections on
the immune responses induced by BCG vaccinated mice, the levels
of cytokine production in pulmonary CD4 and CD8 T cells was
assessed. For this study, the extent of cytokine expression was
determined by evaluating the median fluorescence intensities
(MFI) of the experimental lung cells. In contrast to the cellular
frequencies of pulmonary cells from BCG vaccinated mice, IFN-c
MFI values for CD4 MFT cells remained elevated throughout the
study. As expected, the levels of IFN-c expressed in IFN-c/TNF-a
and triple positive CD4 MFT cells from BCG vaccinated mice
were increased 4–11 fold (relative to monofunctional IFN-c
producing CD4 T cells) during the entire study. Although the IFN-
c MFI values for CD4 MFT cells from BCG immunized mice
were not effected at 7 and 10 weeks after the malaria challenge,
the extent of IFN-c expression in triple-positive CD 4 T cells was
reduced 60% in the malaria infected, BCG vaccinated animals
compared to the BCG vaccinated controls at 2 weeks post P. yoelii
challenge (Figure 6). While the impact of BCG vaccination was
minimal at the later time points, substantially elevated IFN-c MFI
values were detected in CD8 T cells at the 2 week time point.
Relative to monofunctional cells, increased IFN-c MFI values (5–
35 fold) were detected by flow cytometric analysis of IFN-c/TNF-
a and IFN-c/TNF-a/IL2 producing cells at the early time point.
Figure 3. Infection with P. yoelii malaria does not decrease the
acute anti-tuberculosis pulmonary protection induced by
immunization with the M. tuberculosis ESAT6-Antigen 85 fusion
protein formulated in DDA/MPL adjuvant. C57Bl/6 mice were
vaccinated once with BCG or three times two weeks apart the E6-85/
adjuvant vaccine and were infected with P. yoelii two months after the
initial vaccination. The mice were aerogenically challenged with virulent
M. tuberculosis at 2 weeks after the P. yoelii infection and pulmonary
mycobacterial CFU were detemined at 4 weeks post-challenge. The
asterisks show significant CFU differences (p,0.05) relative to naı ¨ve
controls.
doi:10.1371/journal.pone.0028164.g003
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CD8 MFT cells recovered from malaria infected, BCG vaccinated
mice at the peak of the P. yoelii infection. In these mice, the IFN-c
MFI values were decreased by 79% (IFN-c/TNF-a CD8 cells) and
98% (triple positive CD8 cells) by the malaria infection.
Similarly, elevated TNF-a MFI values for CD4 T cells of BCG
vaccinated mice were detected in IFN-c/TNF-a double positive
(increased 5 fold compared to monofunctional cells) and triple
positive MFT cells (22 fold increase) at the two week time point
(Figure 7). In contrast, for the malaria infected, BCG vaccinated
mice, the TNF-a MFI values of CD4 T cells were strikingly reduced
in IFN-c/TNF-a (70% reduction) and triple positive cells (89%)
relative to controls not infected with P. yoelii. While significant 2–3-
fold increases in TNF-a MFI values compared to controls were seen
in CD4 MFT cells at the later time points, the malaria infections did
not impact the lower overall MFI values. For CD8 cells,
substantiallyelevated TNF-a MFIvaluesrelative to monofunctional
cells were observed for the IFN-c/TNF-a (88x) and the triple
positive cells at 2 weeks (44x) after the malaria infection. However,
for the malaria infected, BCG vaccinated mice, dramatic declines in
CD8 TNF-a MFI values of .99% were detected in IFN-c/TNF-a
and triple positive CD8 MFT cells at two weeks after the P. yoelii
infection. At 7 and 10 weeks post-infection, consistently low TNF-a
MFI values were seen in all CD8 T cell subsets.
Discussion
An understated concern about the deployment of new TB
vaccines is the unknown impact that infections with other
pathogens prevalent in the area may have on TB vaccine efficacy.
In many areas endemic for tuberculosis, co-infections with
unrelated pathogens are common and these co-infecting agents
may modulate vaccine-induced immune responses. Earlier studies
have shown that concurrent infections can decrease the anti-
tuberculosis protective responses induced by immunization with
BCG. In animal models, helminth infections have been shown to
reduce the efficacy of BCG vaccine to protect against virulent M.
tuberculosis [18]. Exposure to non-tuberculous mycobacteria can
also inhibit the induction of protective immunity to tuberculosis by
BCG immunization [33,34]. In humans, HIV infection can
severely impair the protective immune responses elicited by
vaccination with BCG [20]. With the considerable geographic
overlap in areas endemic for malaria and tuberculosis and the
recent reports of co-infection of these organisms, it is important to
assess the impact of malaria infections on the effectiveness of
vaccines designed to prevent tuberculosis in pre-clinicalanimal
models. Many different animal species are susceptible to
tuberculous infections and artificially infected mice, guinea pigs,
rabbits, and non-human primates (NHP) have been used as
models of TB [35]. While mice (like humans) are relatively
resistant to TB, can be infected by the aerosol route, and have
been successfully used to elucidate host-pathogen interactions, TB
infections of guinea pigs and rabbits yield more relevant lung
pathology. Although the NHP model has been valaubale for
studying TB latency as well as host immune responses, the cost,
BSL-3 space requirements, and the potential for horizontal
transmission of disease has limited its usefulness. Given that we
had previously established standardized and affordable murine
Figure 4. Infection with P. yoelii malaria does not decrease the acute anti-tuberculosis pulmonary protection induced by
vaccination with the DsecADlysA attenuated M. tuberculosis strain mixed with the E6-85/adjuvant formulation or immunization with
the E6-85/adjuvant followed by boosting with TBMVA/IL-15 vaccine. For the DsecADlysA mixture vaccine, C57Bl/6 mice were vaccinated
three times two weeks apart and then were infected with P. yoelii 4 months after the final vaccination. For the prime/boost protocol, mice were
vaccinated with the E6-85/adjuvant formulation three times two weeks apart, and one month later boosted with the TBMVA/IL-15 vaccine twice one
month apart. The mice that had been primed and boosted were infected with P. yoelii two months after the final booster vaccination. All vaccinated
mice were aerogenically challenged with virulent M. tuberculosis at 2 weeks after a P. yoelii infection and pulmonary mycobacterial CFU were
determined at 4 weeks post-challenge. The asterisks show significant CFU differences (p,0.05) relative to naı ¨ve controls.
doi:10.1371/journal.pone.0028164.g004
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malaria co-infection model. In this study, we showed using this
mouse model that P. yoelii malaria co-infections did not have a
significant impact on the capacity of four different M. tuberculosis
vaccine formulations to control pulmonary growth of an acute
virulent M. tuberculosis infection. In repeated experiments, we
demonstrated that the pulmonary protective responses induced by
vaccination with either BCG, the E6-Ag85 TB fusion protein
formulated in adjuvant, a DsecADlysA M..tuberculosis attenuated
strain/protein mixture or a prime-boost strategy involving the E6-
85 antigen preparation and the MVA/IL15/5Mtb vaccine were
not statistically different in immunized mice that had been infected
with P. yoelii relative to uninfected vaccinated controls. These
findings are consistent with results from a malaria chemoprophy-
laxis trial of Nigerian children where the immunogenicity of BCG
vaccine was not affected by the presence of malaria parasitemia
[6]. Collectively, these data suggest that a primary infection with
malaria parasites will likely not significantly impact the capacity of
new TB vaccines to control acute M. tuberculosis infections in
humans.
Although malaria infections in a murine model did not reduce
the overall protection in the lung induced by vaccination against
TB, BCG vaccine-induced pulmonary immune responses were
impacted by elevated malaria parasitemia levels. Published reports
in humans and mice have shown that CD4 and CD8 T cell
responses against malaria or non-malaria antigens can be inhibited
by malaria infections [9,36–39]. In our study, malaria infections
were shown to significantly decrease the frequency of CD4 and
CD8 triple positive MFT cells expressing IFN-c, TNF-a, and IL-2
in lung cells of BCG vaccinated mice when high levels of
parasitemia were present. Moreover, substantial reductions in
cytokine expression (as measured by the median fluorescence
intensity) was seen in lung MFT cells from P. yoelii infected BCG
vaccinated mice relative to uninfected BCG immunized animals.
For example, the IFN-c MFI values decreased by 60% in CD4
triple positive T cells (compared to controls) while a dramatic 98%
reduction in MFI values was detected for the CD8 triple positive
MFT cells recovered from the lungs of P. yoelii infected and BCG
vaccinated mice. Additionally, the TNF-a MFI values for CD8
MFT cells was dramatically decreased by 99%. While a substantial
suppression of specific T cell responses at 2 weeks after the malaria
infection were clearly seen, the mechanisms by which the P. yoelii
infections reduce the activity of these specific T cell subsets are
uncertain. During acute blood stage malaria infections, regulatory
Figure 5. The frequency of CD4 (A) and CD8 (B) MFT cells recovered form the lungs of BCG vaccinated (black bars) and BCG
vaccinated, malaria infected (grey bars) mice at 2, 7, and 10 weeks following the P. yoelii challenge. Lung cells were removed and
pooled from 3 mice per group, stimulated overnight with BCG, and analyzed by multi-parameter flow cytometry to determine the frequency of cells
producing either IFN-c and TNF-a (IFN/TNF), IFN-c and IL-2 (IFN/IL2), TNF-a and IL-2 (TNF/IL2), and IFN-c, TNF-a, and IL-2 (Triple Positive, TP). The data
are presented as the mean frequency 6 SEM for 5 groups of mice. #, Significant differences between the cellular frequencies of the BCG vaccinated
and the BCG vaccinated, malaria infected groups.
doi:10.1371/journal.pone.0028164.g005
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prostaglandin E2 have been identified [9,40]. IL-10, TGF-b, and
PGE2 have been shown to down-regulate general pro-inflamma-
tory T cell responses, especially CD8 T cell responses. Whether
these immune mediators specifically target vaccine-induced MFT
cells is currently unclear. Importantly, the activity of MFT cells
was not substantially impacted by the P. yoelii infection at 7 and 10
weeks after the malaria challenge. At these time points, when the
malaria parasitemia in the blood was undetectable, both the
cellular frequencies and the MFI values of CD4 and CD8 T cell
subsets of the BCG vaccinated and the BCG vaccinated, malaria
infected mice were not significantly different. Our data are
consistent with the results of an earlier study which showed a
substantial recovery of CD8 T cell function at one month after a P.
yoelii infection [9]. Taken together, these data suggest that the
suppression of BCG-induced T cell function by a P. yoelii infection
is short-lived and the malaria-induced suppressive activity wanes
after parasite clearance. It should be noted that a temporal decline
in the frequency of IFN-c, IFN-c/TNF-a, and triple positive
pulmonary T cells was generally observed in BCG vaccinated mice
with or without concurrent P. yoelii infections. These reduced T
cell frequencies seen at 7 and 10 weeks likely resulted because of
the declining numbers of BCG organisms in the lung at 4–5
months after the BCG immunizations [41].
The reduction in CD4 and CD8 triple positive MFT responses
seen in malaria infected animals at 2 weeks after the P. yoelii
infection was surprising because of the previously reported
correlation between vaccine-induced triple-positive cells and
protective immunity. In animal models of Leishmania and M.
tuberculosis, vaccine-induced immune responses from triple positive
MFT cells have correlated with in vivo protection against an
infectious challenge [30–32]. While CD8 T cells are probably not
critical for controlling an acute tuberculous infection in mice, CD4
T cells are clearly essential for limiting the proliferation of the
pathogen in the lung after an aerogenic M. tuberculosis challenge
[42,43]. If there is a linear correlation between the early induction
of triple positive CD4 MFT cells by vaccines and anti-tuberculosis
protection, then the decreased frequencies and intensities of CD4
MFT triple positive cells observed in the flow cytometric studies of
BCG vaccinated malaria infected mice at 2 weeks post-infection
should have resulted in decreased protection. The apparent lack of
correlation between the early levels of vaccine-induced triple
Figure 6. The Median Fluorescent Intensities (MFI) for IFN-c of CD4 (A) and CD8 (B) T cells recovered from the lungs of BCG-
vaccinated (black bars) and BCG vaccinated, malaria infected (grey bars) mice at 2, 7, and 10 weeks following a P. yoelii challenge.
The lung cells were pooled from 3 mice per group, stimulated overnight with BCG, and analyzed by flow cytometry. The MFIs are presented as the
mean MFI 6 SEM for 5 groups. IFN=monofunctional IFN-c producing T cells, IFN/TNF=multifunctional IFN-c and TNF-a expressing T cells, Triple
Positive (TP)=IFN-c, TNF-a, and IL-2 producing T cells. * MFI values for IFN-c that are significantly higher than the monofunctional cells. # IFN-c MFI
responses which are significantly lower in the BCG vaccinated, malaria-infected mice compared to BCG vaccinated controls.
doi:10.1371/journal.pone.0028164.g006
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been caused by the absence of malaria-induced suppression seen at
later time points in the study when pulmonary bacterial burdens
were evaluated. Alternatively, the association between vaccine-
induced MFT cell responses and anti-microbe protection may be
more complex than has been anticipated. Using a SIV macaque
model, Sui et al recently reported that the levels of antigen-specific
CD8 MFT cells correlated with protection but the correlation was
non-linear and involved a threshold-like effect [44]. In studies of
M. tuberculosis vaccines, our group recently showed that the anti-
tuberculosis protective responses evoked by immunization were
also related to the induction of double-positive IFN-c/TNF-a
expressing CD4 T cells [32]. In the current study, the activity of
double-positive CD4 MFT cells (which were not suppressed by the
malaria infection) could have partially compensated for the
reduction of triple-positive CD4 MFT cells seen at two weeks
after the malaria challenge. Clearly more studies including well
designed longitudinal experiments are needed to delineate the role
of vaccine-induced MFT cells in protecting against tuberculous
disease. Improved strategies to efficiently purify MFT cells would
facilitate studies focusing on the function of these vaccine-induced
MFT cells.
An important concern relevant to malaria and tuberculosis co-
infections is whether cellular immunosuppression often associated
with malaria parasitemia could result in increased cases of
clinically detectable tuberculosis. In this study, primary P. yoelii
infections did not exacerbate acute M. tuberculosis lung disease in
non-vaccinated mice. In repeated experiments, no statistical
differences were seen in pulmonary mycobacterial burdens or
lung pathology at one month post-challenge in infected mice
relative to naı ¨ve controls. In earlier studies, Scott et al and Hawkes
et al had reported that malaria exacerbates mycobacterial disease
in acute and latent infection models [45,46]. However, in both
studies only modest increases in organ CFU levels and/or survival
rates were detected. To further examine the impact of P. yoelii
parasitemia on tuberculous disease, we are currently evaluating
whether malaria infections increase the reactivation rate of mice
with low level latent-like TB infections. The results of this study
could be helpful for delineating whether malaria infections can
contribute to the reactivation of latent tuberculosis.
Figure 7. The Median Fluorescent Intensities (MFI) for TNF-a of CD4 (A) and CD8 (B) T cells recovered from the lungs of BCG-
vaccinated (black bars) and BCG vaccinated, malaria infected (grey bars) mice at 2, 7, and 10 weeks following a P. yoelii challenge.
The lung cells were pooled from 3 mice per group, stimulated overnight with BCG, and analyzed by flow cytometry. The MFIs are presented as the
mean MFI 6 SEM for 4 groups. TNF=monofunctional TNF-a producing T cells, IFN/TNF=multifunctional IFN-c and TNF-a expressing T cells, TP (Triple
Positive)=IFN-c, TNF-a, and IL-2 producing T cells. * MFI values for TNF-a that are significantly higher than the monofunctional cells. # TNF-a MFI
responses which are significantly lower in the BCG vaccinated, malaria-infected mice compared to BCG vaccinated controls.
doi:10.1371/journal.pone.0028164.g007
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PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28164Overall, our studies in the mouse model of pulmonary
tuberculosis suggest that primary malaria co-infections should
not significantly impact the efficacy of novel immunization
strategies against tuberculosis. However, to confirm these findings,
well-designed studies are needed in humans to better understand
the complex interactions between these co-infecting organisms.
The results of these studies should facilitate the design of more
effective immunization and therapeutic procedures against
tuberculosis for use in regions with high rates of concomitant
infections.
Supporting Information
Figure S1 H & E stained lung sections from BCG
vaccinated and malaria infected mice after a M.
tuberculosis challenge by the aerosol route. Sections were
obtained from naı ¨ve, BCG vaccinated, non-immunized-malaria
infected and BCG vaccinated-malaria infected mice at 4 weeks
after an aerogenic challenge with M. tuberculosis and analyzed by
computer scanning using an Image pro analysis system. This
analaysis showed no statistical diiferences in the inflammatory
responses for BCG (20.266.4) and BCG/P. yoelii infected mice
(20.969.32). Similarly, significant differences were not seen
between the lung pathology values for naı ¨ve (38.6610.6) and
naı ¨ve/P. yoelii infected (34.963.9) animals.
(TIF)
Figure S2 The frequency of CD4 (A) and CD8 (B)
monofunctional cells recovered form the lungs of BCG
vaccinated (black bars) and BCG vaccinated, malaria
infected (grey bars) mice at 2, 7, and 10 weeks following
the P. yoelii challenge. Lung cells were removed and pooled
form 3 mice per group, stimulated overnight with BCG, and
analyzed by multi-parameter flow cytometry to determine the
frequency of cells producing either IFN-c, TNF-a, or IL-2. The
data are presented as the mean frequency 6 SEM for 4 groups of
mice. #, Significant differences between the cellular frequencies of
the BCG vaccinated and the BCG vaccinated, malaria infected
groups.
(TIF)
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